A–F: Trends of semaglutide and tirzepatide prescription within 6 months of medication eligibility. Abbreviations: BMI, body mass index; GLP-1, glucagon-like peptide-1; RA, receptor agonist; SES, socioeconomic status. Credit: Health Affairs Scholar (2026). DOI: 10.1093/haschl/qxag255
In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not all populations are benefiting from this expansion. As GLP-1 use has increased, disparities in access to these drugs have widened significantly, according to a new study led by researchers at Boston University School of Public Health (BUSPH).
Published in the journal Health Affairs Scholar, the study found that the percentage of patients with overweight or obesity and without type 2 diabetes who filled prescriptions for semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) within six months of becoming eligible surged from 1.9% in 2021 to 16.6% in 2025.
But prescriptions for these medications were lower among men, Black or Hispanic patients, younger or older patients (ages 18–34 or 55–64), patients in a lower BMI category and/or patients whose health care provider was located in a neighborhood with lower socioeconomic status (SES), measured by education levels in the provider’s ZIP code.
These disparities widened over time and were particularly pronounced in 2024 and 2025, after semaglutide and tirzepatide received formal approval by the Food and Drug Administration for chronic weight management in 2021 and 2023, respectively.
By mimicking a natural hormone that helps regulate insulin, blood sugar, appetite and digestion, GLP-1s can help people achieve dramatic weight loss, particularly those who struggle to lose weight through traditional diet and exercise. Health experts worry that persistent challenges with GLP-1 accessibility and affordability are hindering large swaths of eligible people from receiving life-changing and potentially lifesaving treatment.
“Our study focuses on a population that is especially vulnerable to inequities in GLP-1 access,” says study senior author Dr. Andrew Stokes, an associate professor of global health at BUSPH, who studies population health, aging and mortality, including inequities in GLP-1 access.
“We have better treatments for obesity than ever, but access to them hasn’t caught up. It is much easier for people with diabetes to get these drugs covered by insurance. But for people living with overweight or obesity, coverage is very difficult to obtain—even when they qualify—because providers and insurers don’t always view these as conditions that merit treatment. This is a population that has been left behind.”
As these medications continue to gain prominence, the findings underscore the need for health care providers to receive appropriate training and resources about prescribing GLP-1 treatments, as well as the need for improvements in insurance companies’ drug benefit design to ensure that people who qualify for these treatments can easily access them.
“GLP-1 receptor agonists are moving into routine care very quickly, but without deliberate action, these drugs risk widening the health inequities that obesity already reflects,” says study lead and corresponding author Dr. Minh Trung Le, a research data analyst in the Department of Global Health at BUSPH at the time of the study.
Stokes and Le utilized medical claims data from a national database that includes closed claims for more than 175 million patients. For the analysis, they examined health information, GLP-1 treatment and health care provider locations among 512,389 eligible, commercially insured patients ages 18–64. The analysis did not include patients covered by Medicaid or Medicare, people without insurance or prescriptions obtained through direct-to-consumer channels.
Despite the nearly ninefold rise in GLP-1 prescriptions among eligible patients during the study period, the researchers point out that the vast majority of eligible patients still do not receive these prescriptions for weight management. People with employer-sponsored and other commercial insurance are more likely to have access to GLP-1s.
That racial disparities in access to these medications were still evident among the study’s commercially insured participants underscores the long-standing structural barriers to health care that Black and Hispanic patients experience, even as they are burdened by obesity and other health conditions at greater rates than other populations. Black and Hispanic patients are more likely to face biases and stigma in health care, mistrust of the health care system and higher medication costs, all of which can exacerbate racial disparities in GLP-1 uptake.
The expansion in GLP-1 medication use also disproportionately benefited patients who saw providers in higher-SES neighborhoods. These SES disparities were smaller in the beginning of the study period but widened over time and were larger among patients in lower BMI categories. These disparities were also particularly pronounced among men, which the researchers say may reflect men’s lower likelihood of seeking weight-management care.
“Patients seen at clinics in lower socioeconomic neighborhoods had about 35% lower odds of being prescribed semaglutide or tirzepatide in 2024–2025; early on, that gap was about 15%,” says Le. Insurance coverage alone doesn’t close the gap, he says. “We need to look at how drug benefits are designed, including prior authorization, step therapy and out-of-pocket costs that land unevenly on different patients. We also need to give under-resourced practices real support, such as help with prior-authorization paperwork, so that a clinic’s administrative capacity doesn’t decide who gets treated.”
“These important results show how emerging patterns of GLP-1 access reflect the inequity and fragmentation of our overall health care system, where access to affordable care is all too often a function of where you work, what state you live in or how much money you have,” says Dr. Katherine Hempstead, who was not involved in the study and is a senior policy officer at the Robert Wood Johnson Foundation studying health issues and policies related to health insurance, costs and access to care.
Wealthier patients—many of whom may not clinically qualify for weight-management medications—are often able to leverage their network and resources to pay out of pocket for these medications, she adds. “The new direct-to-consumer channels for GLP-1s are increasing inequity, as ability to pay, rather than need or potential benefit, is what determines access. Because of the poor incentives and shortsightedness in our system, we are leaving major population health benefits on the table, since many of those who would benefit the most from these medications can’t afford them.”
The researchers say the findings add urgency to a growing shift in the health care field to view obesity as a chronic disease, rather than a personal responsibility or lifestyle failure.
“A doctor would never tell a patient with diabetes or with heart disease that their only option is to ‘modify their dietary regimens’ or ‘exercise more,'” Stokes says. “When you think about obesity as a disease, it implies the value of effective medical treatment for the clinical factors that need to be addressed.”
More information
Minh Trung Le et al., Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment, Health Affairs Scholar (2026). DOI: 10.1093/haschl/qxag255
Clinical categories
Weight managementEndocrinology
Provided by
Boston University
Citation:
Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss (2026, November 21)
retrieved 21 November 2026
from https://medicalxpress.com/news/2026-11-soaring-demand-glp-1s-eligible.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.